Skip to main content
. 2011 May 7;60(9):1243–1255. doi: 10.1007/s00262-011-1024-4

Table 1.

Expression of PRAME mRNA in human cancer cell lines and normal tissues, and HLA-A0201 protein expression by flow cytometry in cell lines used in this study

Tissues and tumour cell line % of PRAME mRNA expression (Standard deviation) relative to RH18 Type of cell line HLA-A0201 expression
Cancer cell lines
BV173 1.5 (0.6) Pre-B leukaemia ++
BJAB 99 (3) Pre-B leukaemia ++
Jekka 20 (0.8) Pre-B leukaemia ++
NALM-1 0.1 (0.001) Pre-B leukaemia +
NALM-6 0.2 (0.001) Pre-B leukaemia +
NALM-17 2 (0.2) Pre-B leukaemia +
NALM-20 3 (0.3) Pre-B leukaemia +
NALM-27 1.2 (0.3) Pre-B leukaemia +
REH 32 (0.2) Pre-B leukaemia
K562 312000 (20) Chronic myelogenous leukaemia
Mott 4 132 (3.6) Acute T-cell leukaemia,
HL60 110 (6) Acute promyelocytic leukaemia
Daudi 14.9 (1) Burkitt’s lymphoma
Raji 0.3 (0.1) Burkitt lymphoma
U937 70.8 (0.2) Histiocytic lymphoma
MDA-MB-231 1.9 (0.1) Breast adenocarcinoma +++
ZR-1-75-1 1.4 (0.1) Breast adenocarcinoma
MCF-7 145 (5.6) Breast adenocarcinoma ++
SHSY5Y 241 (5) Neuroblastoma
LAN-1 110 (6) Neuroblastoma
SK-N-AS 0.1 (0.1) Neuroblastoma
TC32 21 (2.1) Ewing sarcoma ++
RH1 26 (1.5) Ewing sarcoma +
RH18 100 (1) Rhabdomyosarcoma ++
SW480 1.2 (0.2) Colon adenocarcinoma ++
SW1116 8.9 (0.5) Colon adenocarcinoma
Colo205 1.3 (0.1) Colon adenocarcinoma +
SK-col-1 107 (3) Colon adenocarcinoma
SW403 184 (7.9) Colon adenocarcinoma ++
Non-malignant cell line
T2 0.2 (0.01) TAP-deficient Lymphoblastoid cell ++
Primary cells
G-7 2 (0.4) Acute lymphoblastic leukaemia ++
Normal tissue
Testis 17.20 (0.01)
Kidney 13.4 (0.031)
Bone marrow 5.95 (0.025)
Liver 2.35 (0.001)
Salivary gland 2.35 (0.001)
Prostate 2.3 (0.013)
Spleen 2.3 (0.1)
Brain 1.2 (0.01)
Skeletal muscle 1.2 (0.01)
Small intestinal 1.18 (0.012)
Stomach 0.7 (0.021)
Colon 0.66 (0.001)
Lung 0.6 (0.022)
Heart 0.1 (0.011)
Placenta 0 (0.001)

Percentage PRAME expression is relative to RH18